CTIC ... Analisi tecnica, fondamentale e news

[amedeo8]

Cti Biopharma Corporation (NASDAQ:CTIC) Sellers Increased By 6% Their ShortsLinda Rogers • February 23, 2016


The stock of Cti Biopharma Corporation (NASDAQ:CTIC) registered an increase of 6% in short interest. CTIC’s total short interest was 14.37 million shares in February as published by FINRA. Its up 6% from 13.56M shares, reported previously. With 2.12M shares average volume, it will take short sellers 7 days to cover their CTIC’s short positions. The short interest to Cti Biopharma Corporation’s float is 12.62%. The stock decreased 1.46% or $0.01 during the last trading session, hitting $0.68. About 5.04M shares traded hands or 45.24% up from the average. CTI BioPharma Corp (NASDAQ:CTIC) has declined 64.21% since July 20, 2015 and is downtrending. It has underperformed by 55.69% the S&P500.

 

[amedeo8]

Pedala / pedala .......... siam tornati come ai primi di febbraio

p.s. aspettando ................ Gennaro

p.p.s. Grafico gentilmente concesso dal............. SuperBikers ........ Old / Giorgio

 

[amedeo8]

CTI BioPharma Corp (NASDAQ:CTIC) Making A Comeback | Insider Financial

CTI BioPharma Corp (NASDAQ:CTIC) Making A Comeback
By Alex Carlson / in Biotech & Pharma, Stocks / on Monday, 22 Feb 2016 09:30 AM /

Source: biopharma-pr.com

Shareholders of CTI Biopharma Corp (NASDAQ:CTIC) were hit with some bad news earlier this month. CTIC received an oral communication from the FDA followed by a letter notifying the company that the company’s IND for pacritinib has been placed on full clinical hold. As a result, the company withdrew its New Drug Application (NDA) as the company reviews the safety and efficacy data from the PERSIST-2 Phase 3 clinical trial and decide next steps. The news sent shares falling and created a buy opportunity for opportunistic investors because while on the surface, the news sounds bad when in reality it’s just a temporary setback. That’s why shares are now making a comeback.

The FDA’s February 8, 2016, letter notes the interim overall survival results from PERSIST-2 showed a detrimental effect on survival consistent with the results from PERSIST-1. The deaths in PERSIST-2 in pacritinib-treated patients include intracranial hemorrhage, cardiac failure and cardiac arrest. The FDA made recommendations that supersede the recommendations made by the FDA in connection with the partial clinical hold imposed by the FDA on February 4, 2016.

The current recommendations include conducting dose exploration studies for pacritinib in patients with myelofibrosis, submitting final study reports and datasets for PERSIST-1 and PERSIST-2, providing certain notifications, revising relevant statements in the related Investigator’s Brochure and informed consent documents and making certain modifications to protocols. In addition, the FDA recommended that the company request a meeting prior to submitting a response to full clinical hold. Under the full clinical hold, all patients currently on pacritinib must discontinue pacritinib immediately and no patients can be enrolled or start pacritinib as initial or crossover treatment. All clinical investigators worldwide have been delivered a notice of the full clinical hold.

Pacritinib is an oral tyrosine kinase inhibitor (TKI) with activity against two important activating mutations: Janus Associated Kinase 2 (JAK2) and FMS-like tyrosine kinase 3 (FLT3). Jakafi is currently the treatment of choice for MF patients. However, patients that have platelet count below 50,000 can only be administered 5mg twice daily dose of Jakafi. At this level, Jakafi is not as effective as at the highest dosage of 20mg a day. For patients with platelet count below 50,000, pacritinib could become the treatment of choice. Jakafi has also shown to have adverse myelosuppressive effects on a fair number of patients whose disease progresses to the point they also become transfusion dependent.

Roughly 25% of the MF patient population have platelet levels below 100,000/uL or 50,000/uL. The company currently has a commercialization agreement with Baxalta. CTIC and Baxalta will jointly commercialize the drug in the U.S. and Baxalta has exclusive commercialize rights for all indications outside the U.S. for which CTIC will receive royalties on ex-U.S. sales.

It’s important for investors to keep a couple of things in mind. CTIC started PERSIST-1 trial with two groups, one on pacritinib and one control group. After 24 weeks they allowed whoever wanted from control group to crossover to pacritinib group. In view of an Independent Data Monitoring Committee (IDMC) they were advised not to allow crossover as this may confound the interpretation of safety as well as the evaluation of survival.

The FDA is now simply reviewing the trial and its faulty design which after 24 weeks allowed for treated and non-treated patients to be in the pacritinib group. The FDA accepted the design originally but it now looks like they are understanding that the study would be invalid if they continue as is and they seem to be using the same terminology as IDMC in their earlier recommendation. Most likely, patients in the control group that experience progression of the disease are likely to want to crossover to pacritinib treatment and those in control group and who feel alright with the best available treatment are not switching to pacritinib. As a result, the pacritinib group after 24 weeks became a mix of patients skewing the trial results.

The key for investors to understand is that it was the design of the trial that was faulty and not pacritinib. The FDA is actually doing CTIC a favor and allowing for the study to be corrected instead of continuing and the FDA having to reject the application. A rejection is that last thing shareholders want to see. Instead, management can now work with the FDA and modify the study so a rejection will be unlikely. The good news is that from the evidence we’ve seen, some patients were seeing benefits from pacritinib. This is great news and investors just need to be more patient. As CEO James Bianco said:

“While we were disappointed and surprised by the FDA’s decision to place pacritinib’s IND on full clinical hold, our priority and sense of purpose has always been to do what is best for patients. There remains a significant unmet medical need in the treatment of myelofibrosis, especially for those with low platelet counts. We continue to see the potential of pacritinib to help this patient population and we are committed to resolving the FDA’s concerns in order to identify a path forward. Additionally, we plan to define the registration path for tosedostat, which recent interim data from a cooperative group study showed the potential therapeutic utility of this oral aminopeptidase inhibitor for older patients with AML and high-risk MDS. We ended the year with a strong financial position that we believe will enable us to achieve our goals in 2016 and beyond.”
ctic 2.22

CTIC is well-positioned to weather the storm. As of December 31, 2015, cash and cash equivalents totaled $128.2 million, compared to $70.9 million as of December 31, 2014. Considering that it’s current market cap is just $183 million, CTIC still looks like a great investment when one does a deep dive analysis and sees that the recent news is just a temporary setback and shares are a buying opportunity at current levels. We will be updating Insider Financial as soon as we know more. For continuing coverage on CTIC and our other hot stock picks, sign up to Insider Financial today and get our next hot stock pick!

 

[Matt077]

 

[Matt077]

Interessante anche questo, anche se parla del Persist-I

(Alessandro Vannucci, Universita' di Firenze)

 

[paoloc72]

Grazie Matt, in poche parole cosa dice ?

 

[Matt077]

Grazie Matt, in poche parole cosa dice ?

Niente di "nuovo" credo (non ho seguito i migliaia di messaggi sugli altri thread).

Che "semplicemente" il Persist-II includeva pazienti piu' gravi rispetto al Persist-I su cui altri trattamenti avevano gia fallito in precedenza. Quindi al momento dell'intervist era ancora difficile dire se le morti sono dovute davvero al farmaco o al corso terminale del disease.

La cosa piu' interessante e' stata la relativa "tranquillita' dell'investigatore (il tipo intervistato lavora per la Mayo clinic e segue il Persist II). Nonostante le morti ha ribadito piu' volte che il pac non sembrava dare adverse events particolari e sembrava funzionare bene (su quelli non deceduti...)

 

[paoloc72]

Niente di "nuovo" credo (non ho seguito i migliaia di messaggi sugli altri thread).

Che "semplicemente" il Persist-II includeva pazienti piu' gravi rispetto al Persist-I su cui altri trattamenti avevano gia fallito in precedenza. Quindi al momento dell'intervist era ancora difficile dire se le morti sono dovute davvero al farmaco o al corso terminale del disease.

La cosa piu' interessante e' stata la relativa "tranquillita' dell'investigatore (il tipo intervistato lavora per la Mayo clinic e segue il Persist II). Nonostante le morti ha ribadito piu' volte che il pac non sembrava dare adverse events particolari e sembrava funzionare bene (su quelli non deceduti...)

Gentilissimo !!!

 

[mistoborsa65]

Gentilissimo !!!

vediamo domani che succederà....

 

[amedeo8]

 

[amedeo8]

Parlando di titoli speculativi, non ho postato un grafico di iShares Nasdaq Biotechnology ( IBB ) in un lungo tempo. Stocks Biotech hanno beneficiato poco dal rally in corso come IBB in gran parte ha sbattuto in una gamma stretta in quanto il rimbalzo iniziale da febbraio 11 bassi. Oggi, IBB è sceso del 3,6%.

iShares Nasdaq Biotechnology (IBB) sta lottando con forza per riprendere a fare progressi.

iShares Nasdaq Biotechnology (IBB) sta lottando con forza per riprendere a fare progressi.

 

[flucio52]

CTI BioPharma Corp. (CTIC) Pre-mercato Trading - NASDAQ.com
$.58* +0.0116 +2.04%
*Ritardato - Al 03/09/2016 07:53

 

[amedeo8]

Buy and Sell reasons for CTIC — Cell Therapeutics In
Mon, Mar 14, 2016

No reasons to buy

6 reasons to sell

-$0.65
Earnings are negative
Earnings per share are negative

77.52%
Short Ratio higher than sector
Short Interest Ratio is higher than sector.

55.64%
Short Ratio higher than industry
Short Interest Ratio is higher than industry.

0.08x
PB Ratio higher than sector
Price-to-Book is higher than sector.

0.12x
PB Ratio higher than industry
Price-to-Book Ratio is higher than industry.

-63.01%
Below SMA 200
The price is below SMA for 200 days period
Basic

1yr Expected Return
-46.62%

1yr Risks (Volatility)
101.19%

1yr Beta
0.05

Market capital
$147M

Employees
155

Money
Book Value
$0.19

Wall Street price
$2.31

Profitability (EPS)
$-0.65

 

[idnid]

stiamo organizzando una sorpresina a bianco , quindi vi chiedo di mandare email alla vostra banca per chiarire la modalità di voto in occasione della assemblea di aprile ...


fate girare la voce , gente è nell'interesse di tutti che si voti questa volta , chi aveva azione alla record date del 26 febbraio ha diritto al voto , pertanto se uniamo le forze + sorpresina possiamo far fare una brutta giornata anche a bianco il 29 aprile .....

vediamo di informare tutti , almeno quelli che hanno interesse long , per gli shortisti che si levino dalle palle , grazie

 

[sandro tr]

stiamo organizzando una sorpresina a bianco , quindi vi chiedo di mandare email alla vostra banca per chiarire la modalità di voto in occasione della assemblea di aprile ...


fate girare la voce , gente è nell'interesse di tutti che si voti questa volta , chi aveva azione alla record date del 26 febbraio ha diritto al voto , pertanto se uniamo le forze + sorpresina possiamo far fare una brutta giornata anche a bianco il 29 aprile .....

vediamo di informare tutti , almeno quelli che hanno interesse long , per gli shortisti che si levino dalle palle , grazie

io il mio lo sto facendo (azione di proselitismo )

una preghiera per le vittime di Bruxelles figlie di questa politica indolente, annichilente e contraria ad ogni elemento di realismo

 

[amedeo8]

OCCHIOOOoooooooo ........ forse si rialza il ventooooooo/ ristorno

Tira di più un Gap a 0,34$ per supporto 0,30$ che un paio di Buoiiiiiiiii

p.s. la tenuta di 0,49$ è fondamentale.......... il bel Tempo solo con chiusura sopra 0,55$ confermata ???

 

[amedeo8]

Visto dopo aver fatto il grafico / J.B. ......... REGOLA il VALORE / ANDAMENTO FUTURO !!!

P.S. A quando il prox REVERSE / SPLIT ???

Cell Therapeutics's President and CEO just disposed of 318,169 shares
What does this mean?

James A Bianco, Cell Therapeutics's President and CEO and a director of the company, recently disposed of 318,169 shares of the company. The disposals took place at $0.55 per share, on March 21, 2016. Bianco still owns 1,820,133 shares of the company. Bianco operates out of Seattle, WA. Some additional info was provided as follows:

The sale was effected pursuant to a Rule 10b5-1 trading plan.
The above information was disclosed in a filing to the SEC. To see the filing, click here.



Other recent filings from the company include the following:

EVP of Cell Therapeutics just disposed of 46,556 shares - March 23, 2016
EVP of Cell Therapeutics just disposed of 45,935 shares - March 23, 2016
Departure of Directors or Certain - March 23, 2016
EVP of Cell Therapeutics just disposed of 63,874 shares - March 23, 2016

 

[Fiber]

Visto dopo aver fatto il grafico / J.B. ......... REGOLA il VALORE / ANDAMENTO FUTURO !!!

P.S. A quando il prox REVERSE / SPLIT ???

Cell Therapeutics's President and CEO just disposed of 318,169 shares
What does this mean?

James A Bianco, Cell Therapeutics's President and CEO and a director of the company, recently disposed of 318,169 shares of the company. The disposals took place at $0.55 per share, on March 21, 2016. Bianco still owns 1,820,133 shares of the company. Bianco operates out of Seattle, WA. Some additional info was provided as follows:

The sale was effected pursuant to a Rule 10b5-1 trading plan.
The above information was disclosed in a filing to the SEC. To see the filing, click here.



Other recent filings from the company include the following:

EVP of Cell Therapeutics just disposed of 46,556 shares - March 23, 2016
EVP of Cell Therapeutics just disposed of 45,935 shares - March 23, 2016
Departure of Directors or Certain - March 23, 2016
EVP of Cell Therapeutics just disposed of 63,874 shares - March 23, 2016

Amedeo ..vediamo anche dopo queste ennesime vendite dove finisce il titolo dall'"Analisi Tecnica" dei sell imperterriti e seriali del dottor James che la fanno da padrona da 2,5$... ovvero da un +400% fà


ocio che quà c'è una lista da far paura



Cohen Milstein Sellers & Toll PLLC Announces the Investigation of CTI BioPharma Corp. -- CTICGlobeNewswire (Thu, Mar 10 2016)

SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action Against CTI BioPharma Corp. (CTIC) and Lead Plaintiff Deadline: April 11, 2016PR Newswire (Thu, Mar 10 2016)

EQUITY ALERT: Rosen Law Firm Announces Filing of Securities Class Action Lawsuit Against CTI BioPharma Corp. – CTICGlobeNewswire (Mon, Mar 7 2016)

Michael Castor’s Sio Capital Management’s New Bets For This Quarterat Insider Monkey (Wed, Mar 2 2016)

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders With Losses on Their Investment in CTI BioPharma Corp. of Class Action Lawsuit and Upcoming Deadline – CTICGlobeNewswire (Sat, Feb 27 2016)

INVESTOR ALERT: Khang & Khang LLP Announces an Investigation of Claims Against CTI BioPharma Corp. and Strongly Encourages Investors to Contact the FirmBusiness Wire (Wed, Feb 24 2016 )

Lifshitz & Miller Law Firm Announces Investigation of Cigna Corporation, CTI Biopharma Corp., G. Willi-Food International Ltd., MannKind Corporation, Navient Corporation, Primero Mining Corp., and Skullcandy, Inc.<acronym title="Google Page Ranking">PR</acronym> Newswire (Tue, Feb 23 2016 )

The Law Offices of Howard G. Smith Announces The Filing Of A Securities Class Action On Behalf Of CTI BioPharma Corp. InvestorsBusiness Wire (Tue, Feb 23 2016)

STOCK ALERT: Rosen Law Firm Reminds CTI BioPharma Corp. Investors of Important Deadline in Class Action – CTICBusiness Wire (Mon, Feb 22 2016)
C 22)

Federman & Sherwood Announces Filing of Securities Class Action Lawsuit Against CTI BioPharma Corp.Marketwired (Tue, Feb 2016)

 

[amedeo8]

Amedeo ..vediamo anche dopo queste ennesime vendite dove finisce il titolo dall'"Analisi Tecnica" dei sell imperterriti e seriali del dottor James che la fanno da padrona da 2,5$... ovvero da un +400% fà


ocio che quà c'è una lista da far paura



Cohen Milstein Sellers & Toll PLLC Announces the Investigation of CTI BioPharma Corp. -- CTICGlobeNewswire (Thu, Mar 10 2016)

SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action Against CTI BioPharma Corp. (CTIC) and Lead Plaintiff Deadline: April 11, 2016PR Newswire (Thu, Mar 10 2016)

EQUITY ALERT: Rosen Law Firm Announces Filing of Securities Class Action Lawsuit Against CTI BioPharma Corp. – CTICGlobeNewswire (Mon, Mar 7 2016)

Michael Castor’s Sio Capital Management’s New Bets For This Quarterat Insider Monkey (Wed, Mar 2 2016)

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders With Losses on Their Investment in CTI BioPharma Corp. of Class Action Lawsuit and Upcoming Deadline – CTICGlobeNewswire (Sat, Feb 27 2016)

INVESTOR ALERT: Khang & Khang LLP Announces an Investigation of Claims Against CTI BioPharma Corp. and Strongly Encourages Investors to Contact the FirmBusiness Wire (Wed, Feb 24 2016 )

Lifshitz & Miller Law Firm Announces Investigation of Cigna Corporation, CTI Biopharma Corp., G. Willi-Food International Ltd., MannKind Corporation, Navient Corporation, Primero Mining Corp., and Skullcandy, Inc.<acronym title="Google Page Ranking">PR</acronym> Newswire (Tue, Feb 23 2016 )

The Law Offices of Howard G. Smith Announces The Filing Of A Securities Class Action On Behalf Of CTI BioPharma Corp. InvestorsBusiness Wire (Tue, Feb 23 2016)

STOCK ALERT: Rosen Law Firm Reminds CTI BioPharma Corp. Investors of Important Deadline in Class Action – CTICBusiness Wire (Mon, Feb 22 2016)
C 22)

Federman & Sherwood Announces Filing of Securities Class Action Lawsuit Against CTI BioPharma Corp.Marketwired (Tue, Feb 2016)

CTIC torna a chiudere il gap a 0,34$ e se non basta .......... doppio minimo

No problem cause / il fratello LUIS è un'artista............. se non era per lui era da mò che avevano chiuso bottega

 

[amedeo8]

Cti Biopharma Corporation (NASDAQ:CTIC) Shorts Decreased by 15.15% After Short Covering

MARCH 28, 2016 BY STAFF WRITER IN STOCK NEWS · 0 COMMENT


The stock of Cti Biopharma Corporation (NASDAQ:CTIC) registered a decrease of 15.15% in short interest. CTIC’s total short interest was 13.91M shares in March as published by FINRA. Its down 15.15% from 16.39 million shares, reported previously. With 1.38M shares average volume, it will take short sellers 10 days to cover their CTIC’s short positions. The short interest to Cti Biopharma Corporation’s float is 6.96%. The stock decreased 2.07% or $0.011 during the last trading session, hitting $0.502. About 633,939 shares traded hands. CTI BioPharma Corp (NASDAQ:CTIC) has declined 68.94% since August 20, 2015 and is downtrending. It has underperformed by 66.84% the S&P500.

CTI BioPharma Corp. , formerly Cell Therapeutics, Inc., is a biopharmaceutical firm focused on the acquisition, development and commercialization of targeted therapies covering a spectrum of blood-related cancers that offer a benefit to patients and healthcare providers. The company has a market cap of $138.77 million. The Firm is focused on commercializing PIXUVRI (pixantrone), or PIXUVRI, in the European Union, for the treatment of adult patients with multiply relapsed or refractory aggressive B-cell non-Hodgkin lymphoma (NHL), and conducting a Phase III clinical trial program of pacritinib for the treatment of adult patients with myelofibrosis to support regulatory submission for approval in the United States and Europe. It currently has negative earnings. It is also engaged in evaluating pacritinib in earlier clinical trials as treatment for other blood-related cancers.

The institutional sentiment decreased to 0.6 in Q3 2015. Its down 0.74, from 1.34 in 2015Q2. The ratio dived, as 17 funds sold all CTI BioPharma Corp shares owned while 30 reduced positions. 9 funds bought stakes while 19 increased positions. They now own 59.35 million shares or 22.89% more from 48.30 million shares in 2015Q2.

Bvf Inc Il holds 2.95% of its portfolio in CTI BioPharma Corp for 10.00 million shares. Lombard Odier Asset Management (Usa) Corp owns 1.30 million shares or 0.17% of their US portfolio. Moreover, Consonance Capital Management Lp has 0.09% invested in the company for 460,000 shares. The Missouri-based First Heartland Consultants Inc. has invested 0.05% in the stock. Washington Trust Co, a Rhode Island-based fund reported 410,616 shares.

Since March 6, 2015, the stock had 0 insider buys, and 3 selling transactions for $55,339 net activity. Bianco Louis A sold 10,000 shares worth $15,800. Singer Jack W sold 15,000 shares worth $24,335. Plunkett Matthew sold 10,000 shares worth $15,204. Nudelman Phillip M Phd sold 150,000 shares worth $217,502. The insider Love Richard L sold 13,660 shares worth $19,853.